One-year clinical outcomes after prolapse surgery with nonanchored mesh and vaginal support device

Purpose. To compare clinical outcomes following LASIK for myopia performed with MEL 90 vs. Schwind Amaris 750S excimer laser. Methods. Data were collected retrospectively for patients who underwent Femto-LASIK, using the MEL 90 and Schwind Amaris 750S excimer laser for correction of myopia and myopic astigmatism within the range of −1.00 to −10.00 D SE from January 2013 till June 2018. Outcomes were analysed at 12 months for safety, efficacy, enhancement rate, and long-term complications. Results. A total of 328 eyes of 328 patients were analysed. One hundred and sixty-three eyes were treated with Schwind Amaris and the remaining 165 eyes with the MEL 90 laser. Twelve months postoperatively, the mean UDVA, CDVA, residual SE, and cylinder in the Amaris group were −0.10 ± 0.09 logMAR, −0.14 ± 0.06 logMAR, −0.21 ± 0.22 D, −0.13 ± 0.18 D versus −0.05 ± 0.07 logMAR, −0.09 ± 0.08 logMAR, −0.23 ± 0.23 D, and −0.14 ± 0.21 D for the MEL 90 group ( p values >0.05). For the Amaris group, safety and efficacy indices were 1.12 and 1.02, whereas for the MEL 90 group, these indices were 1.08 and 1.00, respectively. No eye in either group had any postop flap-related complications, infectious keratitis, diffuse lamellar keratitis, or keratectasia. Two eyes in the Amaris and 4 eyes in MEL 90 group required enhancement for the progression of myopia. Conclusion. At 12 months, both Schwind Amaris 750S and MEL 90 lasers demonstrated comparable clinical outcomes for myopic LASIK in a single surgeon setting.

Download Full-text

P4663The predictive value of neuron-specific enolase after cardiac arrest is higher for one-month clinical outcomes than for one-year mortality: results from a prospective study

European Heart Journal ◽

10.1093/eurheartj/ehy563.p4663 ◽

2018 ◽

Vol 39 (suppl_1) ◽

Author(s):

D Vondrakova ◽

A Kruger ◽

M Janotka ◽

J Naar ◽

V Dudkova ◽

...

Keyword(s):

Cardiac Arrest ◽

Prospective Study ◽

Clinical Outcomes ◽

Predictive Value ◽

Neuron Specific Enolase ◽

One Year ◽

A Prospective Study

Download Full-text

Subspinal impingement: clinical outcomes of arthroscopic decompression with one year minimum follow up

Knee Surgery Sports Traumatology Arthroscopy ◽

10.1007/s00167-018-4923-5 ◽

2018 ◽

Vol 28 (9) ◽

pp. 2756-2762 ◽

Cited By ~ 3

Author(s):

Frankl Michal ◽

Eyal Amar ◽

Ran Atzmon ◽

Zachary Sharfman ◽

Barak Haviv ◽

...

Keyword(s):

Clinical Outcomes ◽

One Year

Download Full-text

One-year clinical outcomes following theta burst stimulation for post-traumatic stress disorder

Neuropsychopharmacology ◽

10.1038/s41386-019-0584-4 ◽

2019 ◽

Vol 45 (6) ◽

pp. 940-946 ◽

Cited By ~ 4

Author(s):

Nicholas J. Petrosino ◽

Mascha van ’t Wout-Frank ◽

Emily Aiken ◽

Hannah R. Swearingen ◽

Jennifer Barredo ◽

...

Keyword(s):

Transcranial Magnetic Stimulation ◽

Clinical Outcomes ◽

Post Traumatic Stress Disorder ◽

Traumatic Stress ◽

Magnetic Stimulation ◽

Stress Disorder ◽

Post Traumatic Stress ◽

Post Traumatic ◽

One Year ◽

Theta Burst

AbstractTheta burst transcranial magnetic stimulation (TBS) is a potential new treatment for post-traumatic stress disorder (PTSD). We previously reported active intermittent TBS (iTBS) was associated with superior clinical outcomes for up to 1-month, in a sample of fifty veterans with PTSD, using a crossover design. In that study, participants randomized to the active group received a total of 4-weeks of active iTBS, or 2-weeks if randomized to sham. Results were superior with greater exposure to active iTBS, which raised the question of whether observed effects persisted over the longer-term. This study reviewed naturalistic outcomes up to 1-year from study endpoint, to test the hypothesis that greater exposure to active iTBS would be associated with superior outcomes. The primary outcome measure was clinical relapse, defined as any serious adverse event (e.g., suicide, psychiatric hospitalization, etc.,) or need for retreatment with repetitive transcranial magnetic stimulation (rTMS). Forty-six (92%) of the initial study’s intent-to-treat participants were included. Mean age was 51.0 ± 12.3 years and seven (15.2%) were female. The group originally randomized to active iTBS (4-weeks active iTBS) demonstrated superior outcomes at one year compared to those originally randomized to sham (2-weeks active iTBS); log-rank ChiSq = 5.871, df = 1, p = 0.015; OR = 3.50, 95% CI = 1.04–11.79. Mean days to relapse were 296.0 ± 22.1 in the 4-week group, and 182.0 ± 31.9 in the 2-week group. When used, rTMS retreatment was generally effective. Exploratory neuroimaging revealed default mode network connectivity was predictive of 1-year outcomes (corrected p < 0.05). In summary, greater accumulated exposure to active iTBS demonstrated clinically meaningful improvements in the year following stimulation, and default mode connectivity could be used to predict longer-term outcomes.

Download Full-text